

BIOLIDICS LIMITED
(Company Registration No. 200913076M)
(Incorporated in the Republic of Singapore)

POPOSED SUBSCRIPTION OF 230,769,231 NEW ORDINARY SHARES IN THE ISSUED SHARE CAPITAL OF BIOLIDICS LIMITED (THE “COMPANY”) BY MR. ZHU HUA (THE “PROPOSED SUBSCRIPTION”)

- RECEIPT OF LISTING AND QUOTATION NOTICE

The Board of Directors (the “**Board**”) of the Company refers to the Company’s announcement dated 12 October 2023 in relation to the Proposed Subscription (“**Announcement**”). Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Announcement.

The Board wishes to announce that the Company has on 26 October 2023, received the listing and quotation notice from the SGX-ST (“**LQN**”) for the listing and quotation of the Subscription Shares on the Catalist Board of the SGX-ST, subject to:

- (i) the Company obtaining shareholders’ approval for the Proposed Subscription at an extraordinary general meeting; and
- (ii) the Company’s compliance with the SGX-ST’s listing requirements.

The LQN is not to be taken as an indication of the merits of the Proposed Subscription, the Subscription Shares, the Company, its subsidiaries and their securities.

By Order of the Board

Song Tang Yih
Executive Director and Chief Executive Officer
26 October 2023

This announcement has been prepared by the Company and has been reviewed by the Sponsor for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lim Hoon Khiat, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.